BTA 243
Alternative Names: CL 316243Latest Information Update: 21 Mar 2002
At a glance
- Originator Wyeth
- Class Benzene derivatives; Dicarboxylic acids
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity; Overactive bladder; Type 2 diabetes mellitus
Most Recent Events
- 21 Mar 2002 Discontinued - Preclinical for Overactive bladder in USA (unspecified route)
- 20 Mar 2002 American Home Products and its subsidiary Wyeth-Ayerst are both now called Wyeth
- 05 Oct 2001 Preclinical development for Overactive bladder in USA (Unknown route)